INmune Bio Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

INmune Bio Stock Summary

INmune Bio competes with Tff Pharmaceuticals, Anebulo Pharmaceuticals, AN2 Therapeutics, Cue Biopharma, and Anixa Biosciences. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

INmune Bio Key Financial Ratios

INmune Bio Key Balance Sheet Accounts

INmune Bio Key Cash Accounts

INmune Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining INmune Bio's current stock value. Our valuation model uses many indicators to compare INmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across INmune Bio competition to find correlations between indicators driving INmune Bio's intrinsic value. More Info.INmune Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, INmune Bio's Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the INmune Bio's earnings, one of the primary drivers of an investment's value.

INmune Bio Systematic Risk

Today, most investors in INmune Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various INmune Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of INmune Bio growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of INmune Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of INmune Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of INmune Bio based on widely used predictive technical indicators. In general, we focus on analyzing INmune Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build INmune Bio's daily price indicators and compare them against related drivers.

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.